Nifedipine (Page 5 of 5)

DOSAGE AND ADMINISTRATION

Dosage should be adjusted according to each patient’s needs. It is recommended that nifedipine extended-release tablets be administered orally once daily on an empty stomach. Nifedipine extended-release tablet is an extended release dosage form and tablets should be swallowed whole, not bitten or divided. In general, titration should proceed over a 7 to14 day period starting with 30 mg once daily. Upward titration should be based on therapeutic efficacy and safety. The usual maintenance dose is 30 mg to 60 mg once daily. Titration to doses above 90 mg daily is not recommended.

If discontinuation of nifedipine extended-release tablets is necessary, sound clinical practice suggests that the dosage should be decreased gradually with close physician supervision.

Coadministration of nifedipine with grapefruit juice is to be avoided (see and ). CLINICAL PHARMACOLOGYPRECAUTIONS

Care should be taken when dispensing nifedipine extended-release tablets to assure that the extended-release dosage form has been prescribed.

HOW SUPPLIED

NDC:64725-2057-1 in a BOTTLE of 100 TABLET, EXTENDED RELEASES

The tablets should be protected from light and moisture and stored at 25ºC (77ºF); excursions permitted to 15-30ºC (59-86ºF) [see USP Controlled Room Temperature]. Dispense in tight, light-resistant containers.

Manufactured in Canada by: Valeant Pharmaceuticals International, Inc. Steinbach, MB R5G1Z7 Canada

Manufactured for: TEVA PHARMACEUTICALS USA Sellersville, PA 18960

LB0008-04

Rev. 3/2012

NIFEDIPINE TABLET, EXTENDED RELEASE

Label Image
(click image for full-size original)
NIFEDIPINE
nifedipine tablet, extended release
Product Information
Product Type HUMAN PRESCRIPTION DRUG Item Code (Source) NDC:64725-2057(NDC:0093-2057)
Route of Administration ORAL DEA Schedule
Active Ingredient/Active Moiety
Ingredient Name Basis of Strength Strength
Nifedipine (Nifedipine) Nifedipine 30 mg
Inactive Ingredients
Ingredient Name Strength
ANHYDROUS LACTOSE
ETHYLCELLULOSES
HYDROXYETHYL CELLULOSE (140 MPA.S AT 5%)
HYPROMELLOSES
MAGNESIUM STEARATE
CELLULOSE, MICROCRYSTALLINE
METHYL METHACRYLATE
POLYETHYLENE GLYCOLS
SILICON DIOXIDE
SODIUM LAURYL SULFATE
TALC
TITANIUM DIOXIDE
Product Characteristics
Color YELLOW (Mustard Yellow) Score no score
Shape ROUND Size 9mm
Flavor Imprint Code B;30
Contains
Packaging
# Item Code Package Description Multilevel Packaging
1 NDC:64725-2057-1 100 TABLET, EXTENDED RELEASE in 1 BOTTLE None
Marketing Information
Marketing Category Application Number or Monograph Citation Marketing Start Date Marketing End Date
ANDA ANDA075269 10/18/2012
Labeler — TYA Pharmaceuticals (938389038)
Registrant — TYA Pharmaceuticals (938389038)
Establishment
Name Address ID/FEI Operations
TYA Pharmaceuticals 938389038 RELABEL (64725-2057), REPACK (64725-2057)

Revised: 08/2013 TYA Pharmaceuticals

All MedLibrary.org resources are included in as near-original form as possible, meaning that the information from the original provider has been rendered here with only typographical or stylistic modifications and not with any substantive alterations of content, meaning or intent.

This site is provided for educational and informational purposes only, in accordance with our Terms of Use, and is not intended as a substitute for the advice of a medical doctor, nurse, nurse practitioner or other qualified health professional.

Privacy Policy | Copyright © 2023. All Rights Reserved.